- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Breast cancer
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 520KB)
Olaparib – March 2023
Olaparib: Tablet 100 mg, Tablet 150 mg; Lynparza®
Last updated
14 July 2023